Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy
Authors:ID Vrankar, Martina (Author)
ID Unk, Mojca (Author)
Files:.pdf PDF - Presentation file, download (426,11 KB)
MD5: B22C6F8F9A8C38E9C4B4D6198FFA4FA1
 
Language:English
Typology:1.02 - Review Article
Organization:Logo OI - Institute of Oncology
Abstract:Uncommon responses during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to immunotherapy immune response evaluation criteria solid tumors (iRECIST) were accepted. According to iRECIST, worsening of performance status (PS) accompanied to pseudoprogression reflects most probably the true progression of the malignant disease. Methods. A systematic review of the literature was made by using several electronic database with the following search criteria: symptomatic pseudoprogression, atypical response, immunotherapy and lung cancer. Results. In the literature, we identified five reports of seven patients treated with immunotherapy that met the inclusion criteria. We also report our experience of patient with pseudoprogression and almost complete response after one dose of immunotherapy. Conclusions. As seen from our review, iRECIST criteria might be insufficient in distinguishing true progression from pseudoprogression in some patients with advanced NSCLC treated with immunotherapy. More precise assessment methods are urgently needed.
Keywords:symptomatic pseudoprogression, atypical response, immunotherapy, lung cancer
Publication status:Published
Publication version:Version of Record
Publication date:01.12.2018
Publisher:Association of Radiology and Oncology
Year of publishing:2018
Number of pages:str. 365-369, I
Numbering:Vol. 52, no. 4
Source:Ljubljana
PID:20.500.12556/DiRROS-19080 New window
UDC:616.2
ISSN on article:1318-2099
DOI:10.2478/raon-2018-0037 New window
COBISS.SI-ID:3000699 New window
Copyright:by Authors
Publication date in DiRROS:11.06.2024
Views:340
Downloads:113
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Abstract:Nenavadni odzivi med zdravljenjem z imunoterapijo so nov izziv v vsakdanji onkološki praksi. Sprejeta so bila nova merila za oceno odziva na imunoterapijo, t.i. kriteriji iRECIST. Po teh kriterijih poslabšanje stanja zmogljivosti bolnika, pri katerem ugotavljamo pseudoprogres, predstavlja resnično napredovanje maligne bolezni. Metode. Opravili smo sistematični pregled literature z uporabo več elektronskih podatkovnih baz z naslednjimi iskalnimi kriteriji: simptomatski pseudoprogres, atipični odziv, imunoterapija in pljučni rak. Rezultati. V literaturi smo našli pet poročil o sedmih bolnikih z rakom pljuč, ki so jih zdravili z imunoterapijo in so izpolnjevali merila za vključitev v analizo. V članku smo predstavili tudi izkušnjo bolnice s pseudoprogresom po le enem odmerku imunoterapije, ki smo jo zdravili na Onkološkem inštitutu v Ljubljani. Zaključki. Po pregledu literature in na podlagi našega primera ugotavljamo, da kriteriji iRECIST za odgovor na imunoterapijo pri nekaterih bolnikih z nedrobnoceličnim rakom pljuč ne zadoščajo za razlikovanje pravega napredovanja rakave bolezni od pseudoprogresa. Nujno potrebujemo natančnejše metode za ocenjevanje odgovora na zdravljenje z imunoterapijo.
Keywords:simptomatski psevdoprogres, atipičen odgovor, imunoterapija, rak pljuč


Back